• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Reed-Lane

    PCI Pharma Services

    Adare Pharma Solutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    Baxter BioPharma Solutions

    Alcami

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    What Drives Mergers & Acquisitions in the Pharma industry?

    A look at the key drivers that force pharma companies to redefine themselves.

    What Drives Mergers & Acquisitions in the Pharma industry?
    What Drives Mergers & Acquisitions in the Pharma industry?
    What Drives Mergers & Acquisitions in the Pharma industry?
    Related CONTENT
    • Navigating Uncertainty: Considerations for Life Sciences 2021
    • Reed-Lane Adds Second Track & Trace Cartoning Line
    • Cell & Gene Therapy Supply Chain: Early Preparation is Key
    • Inspecting the Unexpected
    • The Pandemic & The Pharma Industry: 3 Things to Know
    Dr. Christoph Bieri, Managing Partner, Kurmann Partners AG 01.30.18
    The pharmaceutical industry probably sees more merger and acquisition (M&A) activity than any other industry, both in the number of deals and the amount of money spent on acquisitions and mergers. No other industry can compare when it comes to M&As; large, game-changing deals continuously and profoundly change the competitive landscape, while smaller yet still significant transactions are an integral part the of operations of pharma companies.

    Below we describe key drivers that force pharma companies to redefine themselves, and why large M&A is the preferred way to do so. We continue by describing why M&A is a standard component of the pharma business model. Finally, we conclude by showing M&A transaction patterns in strategic business areas, which corroborate our concepts and hypotheses.

    Key factors triggering changes in the pharma industry
    The single most important driver for changes in the pharma industry is the ever-increasing cost of drug development. Most companies can no longer afford to carry out R&D to find innovative compounds.

    The most-quoted study of drug development costs states that on average, the development of a new drug—a new active pharmaceutical ingredient (API)—costs around $1.4 billion, if pipeline failures are factored in. It usually takes ten years from synthesis to approval, thus $1.2 billion capital costs accrue the to the figure below, which results in average total cost of $2.6 billion to develop a new drug.

    One fundamental reason behind the growing costs is the advancement of medicine. To create value, new drugs need either to solve a problem which has previously been intractable, or be significantly better than what already exists on the market. The other driver for the development costs is the ever-increasing regulatory requirements.

    Today, a company needs to invest between $2-4 billion per year in R&D to have a meaningful portfolio of drug development programs. Putting this in perspective, in the long-term, pharma companies spend 20% of their revenue from high-margin original drugs on R&D. Thus, only companies with revenue of $10 billion or higher from originals can afford to have a substantial drug development program.

    Meanwhile, payors and regulators strive to replace as many off-patent original drugs as possible with generics. Reimbursement prices for generics have been lowered everywhere, leading to major consolidation among generic drug providers.

    Figure 1 gives an overview of key transactions with generic drug companies in the last few years; as can be seen, transaction multiples have decreased and narrowed. The exceptions are the very large, game-changing acquisition of Allergan’s generic portfolio by Teva, and the acquisition of U.S. special generics provider Par Pharma by End. By now we know that TEVA massively overpaid for Allergan. More relevant is the observation that in January 2018, Mallinckrodt apparently failed to find a buyer for its generic portfolio at a valuation of 0.6x sales.

    The third classical segment of Pharma—consumer health/OTC—recently also saw large, industry-shaping transactions involving Novartis/GSK, Merck & Co./Bayer and Boehringer/Sanofi. After a pause in 2016-2017, consolidation is picking up again, with Merck KGaA and Pfizer trying to divest their OTC operations.

    Four strategic archetypes emerge
    In this changing environment, we can observe four distinct strategic archetypes emerging. Originators, the classical pharma model, focus on financing the development and marketing of new drugs. Generic drug providers excel in producing and delivering drugs at a low cost and as a result are fully backward integrated. Consumer health companies promote drugs directly to patients, using mass-consumer marketing techniques, whereas point-of-call specialists are well established in a specific indication or with a specific group of doctors such as Novo Nordisk for diabetes, Lundbeck in psychiatry, Leo Pharma in dermatology, or Norgine in gastroenterology, and by definition, all orphan drug companies.

    As the term itself implies, “archetypes” are strategic focal points companies coalesce to, yet organizations rarely meet these pure definitions. Practical experience however shows that one organization cannot successfully combine several archetypes—a company cannot be a generic drug provider and an originator at the same time, for example. The required business cultures—e.g. fostering innovation by originators vs. controlling costs by generic drug manufacturers—are incompatible.

    Our model is not applicable to emerging markets, and has some limitations for countries with strong local pharma industries such as Japan, Italy and Spain. Also, in the U.S., the regulatory and pricing framework allows for a fifth archetype—developers of advanced generics. Biosimilars are also not discussed as those have their own, emerging market rules.

    Why M&A is used for strategic repositioning?
    There are three basic reasons why pharma companies resort to M&A to implement strategic changes. First, the critical size requirements in each market segment increased much faster than the companies could grow. M&A was unavoidable to build today’s originators and generic drug providers. None of the players from 20 years ago could have succeeded on their own. The second reason is the fundamental nature of the required changes. Large mergers allow bundling of sub-critical businesses, to change the culture and to build new platforms.

    The third reason is that, except for the effects triggered by a patent cliff, changes in the pharma market are glacial compared to other industries. Hence the top tier of the industry is remarkably stable. Of the 10 largest pharma industry players by sales, only one (Gilead) has roots of less than 100 years. On the other hand, there are a few biotech companies who became firmly established as originators—Amgen, Biogen and Gilead.

    M&As for efficient capital allocation
    The other driver for M&As is efficient capital allocation across the industry, which applies to two areas: R&D and manufacturing.

    The large, complex organizations of the originators are unsuited to fostering innovation. An ecosystem of venture capital and entrepreneurs has proven much more effective in selecting early-stage biomedical research opportunities and allocating money to those opportunities. Essentially, venture capitalists today pre-finance the early-stage development for pharma companies.

    At the other end of the value chain, originators have started to use M&A to outsource manufacturing, selling plants to contract manufacturing organizations (CMOs) in combination with long-term manufacturing and supply agreements. Besides the cost benefits which these deals typically entail, they also increase the return on capital by reducing the asset base of the originator. The expected return on capital in the relatively stable, low-margin, and capital-intense manufacturing activity is distinctly lower than for the more volatile and more profitable development and marketing of drugs.

    Looking at the big picture—M&A activity pattern
    In Figure 2 we mapped M&A transaction activity over five years from 2013 to 2017 with targets in Western Europe, Canada and the U.S. to the four archetypes and associated business areas. The resulting patterns confirms the trend to be expected based on the above comments. Most activity is seen with innovators as targets. But also manufacturing assets and contract development and manufacturing organizations (CDMOs) have gone through many transactions in this period, which is the result of the fundamental rearrangement of pharma manufacturing and pharma service providers.

    Conclusion
    In conclusion, M&A is a fundamental tool for strategy implementation in the pharma industry. Deal-making is essential to implement game-changing strategic moves to build companies fit to master future challenges. But M&A is also a standard element of the business model for pharma companies to get access to innovation, but also to streamline operations in manufacturing or to prune business portfolios. 


     































     






    Christoph Bieri is managing partner with Kurmann Partners, a Swiss-based M&A boutique focused on mid-market transactions in the pharmaceutical and medtech industries and adjacent segments. Christoph has led numerous buy-side and sell-side international transactions concerning targets based in Europe and North America. Prior to joining Kurmann Partners, Christoph was chief executive officer of a venture-financed R&D technology company for biotechnology, and before that a consultant with The Boston Consulting Group.
    Related Searches
    • patients
    • chief executive officer
    • drug development costs
    • it
    Suggested For You
    Navigating Uncertainty: Considerations for Life Sciences 2021 Navigating Uncertainty: Considerations for Life Sciences 2021
    Reed-Lane Adds Second Track & Trace Cartoning Line Reed-Lane Adds Second Track & Trace Cartoning Line
    Cell & Gene Therapy Supply Chain: Early Preparation is Key Cell & Gene Therapy Supply Chain: Early Preparation is Key
    Inspecting the Unexpected Inspecting the Unexpected
    The Pandemic & The Pharma Industry: 3 Things to Know The Pandemic & The Pharma Industry: 3 Things to Know
    Preparing to Adopt Intelligent Label Management Preparing to Adopt Intelligent Label Management
    Rising to The Occasion: The High Stakes of Vaccine Transport Rising to The Occasion: The High Stakes of Vaccine Transport
    Sai Life Sciences to Expand Biology Capabilities Sai Life Sciences to Expand Biology Capabilities
    BioLife Solutions Secures $2.7 Million Contract BioLife Solutions Secures $2.7 Million Contract
    The Pandemic’s Become an Insurmountable Opportunity The Pandemic’s Become an Insurmountable Opportunity
    Henry Schein Implements TraceLink VRS Solution Henry Schein Implements TraceLink VRS Solution
    Beyond the Boundaries Beyond the Boundaries
    CRO Industry Update CRO Industry Update
    Vetio Animal Health Vetio Animal Health
    Contracting And Outsourcing Agenda Contracting And Outsourcing Agenda

    Related Features

    • Excipients
      Bye-Bye China?

      Bye-Bye China?

      Instead of closing its doors on China, Western pharma industry needs to take a balanced approach and perform proper due diligence based on objective criteria.
      Michele Jermini and Enrico Polastro 11.17.20

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20


    • The Single-Use Mixing Landscape: Evaluating Your Options

      The Single-Use Mixing Landscape: Evaluating Your Options

      Adoption of single-use technologies has increased markedly in recent years and will continue to grow.
      Mark A. Sitcoske, Founder & CEO, High Purity New England 11.17.20

    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      DCAT President Talks COVID-19, Drug Manufacturing and Innovation

      Lonza’s Director of Commercial Development, Sean Diver, was recently named President of DCAT.
      Tim Wright, Editor, Contract Pharma 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20


    • Injectables
      Catering for the Complex

      Catering for the Complex

      The rapidly changing landscape of pharmaceutical packaging.
      Marcelo Cruz, Director Business Development and Marketing, Tjoapack 11.17.20

    • Cold Chain Management | Supply Chain
      Cold Chain Trends

      Cold Chain Trends

      There is a growing need for convenience through Direct-to-Patient and Direct-from-Patient services in clinical trials.
      Vince Paolizzi, Director of NanoCool Sales, Pelican BioThermal 11.17.20

    • Biologics, Proteins, Vaccines | Inspections | Supply Chain
      Inspecting the Unexpected

      Inspecting the Unexpected

      Preparing quality control processes for COVID-19 vaccine candidates.
      Dr. Andrea Sardella and Raffaele Pace, Stevanato Group 11.17.20


    • Scale-up/Technology Transfer
      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Ensuring Quality During the Transfer and Scale Up of Rx Drugs

      Defining the key parameters and considerations for a successful technology transfer.
      Tom Chang, President, Bora Pharmaceutical Laboratory Co. Ltd. 11.17.20

    • Scale-up/Technology Transfer
      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up

      Identifying, assessing and mitigating threats at every stage of the development pipeline.
      Joe Willmot, Application Leader, H.E.L Group 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • APIs
      Understanding the Importance of Crystallization Processes

      Understanding the Importance of Crystallization Processes

      Crystallization is a crucial aspect of a molecule’s development and can be used to avoid unnecessary cost, risk and development delays.
      Dr. Craig Callahan, Project Scientist, Cambrex Edinburgh 10.14.20

    • Capsules | Solid Dosage/Creams/Ointments
      Capsule Technology Trends

      Capsule Technology Trends

      A look at the capsule market with a particular focus on the factors driving increased demand in non-gelatin-based formulations.
      Julien Lamps, Product Manager, Lonza 10.14.20

    • Aseptic Processing | Fill/Finish
      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      A Holistic Cleanroom Concept: Higher Quality and Greater Flexibility

      Overcoming today’s aseptic fill-and-finish process challenges.
      Ute Schleyer, Project Manager, Site & Plant Development, Vetter 10.14.20

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Nexelis Acquires GSK Vax Lab In Marburg
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login